While the role of these effectors has not yet been explored in GNAQ-related vascular anomalies, our results show that MEK/ERK inhibition with Trametinib in the murine model prevented vascular lesions and the associated complications such as coagulopathy, suggesting this pathway is implicated in the disease pathogenesis. This evidence concerns the gene MAP2K7 and blood coagulation disease.